A European Collaborative Study of the Role of CyBorD in the Up-Front Treatment of AL Amyloidosis


A European Collaborative Study of the Role of CyBorD in the Up-Front Treatment of AL Amyloidosis
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Ola Landgren, MD, PhD (2/9/15)
Palladini G et al. A European collaborative study of 230 patients to assess the role of cyclophosphamide, bortezomib and dexamethasone in upfront treatment of patients with systemic AL amyloidosis. Proc ASH 2014;Abstract 305.

Dr Landgren is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York, New York.